These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 2730051)

  • 1. [Role of supporting therapy of Juzentaiho-to (JTT) in advanced breast cancer patients].
    Adachi I; Watanabe T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1538-43. PubMed ID: 2730051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
    Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combination chemo-endocrine therapy of metastatic and stage IV breast cancer with cyclophosphamide, adriamycin, prednisolone and tamoxifen (CAPT)--with special reference to management of brain and liver metastasis].
    Nakamura Y; Kawaguchi M; Hata A; Watanabe H; Ueki Y; Oribe T; Koba F; Takamuku K
    Gan To Kagaku Ryoho; 1989 Feb; 16(2):243-50. PubMed ID: 2919892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen.
    Fornander T; Rutqvist LE; Glas U
    Cancer Treat Rep; 1987; 71(7-8):685-8. PubMed ID: 3300966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
    Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
    Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine.
    Zhou LY; Shan ZZ; You JL
    Chin J Integr Med; 2009 Apr; 15(2):107-11. PubMed ID: 19407947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
    Rose C; Kamby C; Mouridsen HT; Bastholt L; Brincker H; Skovgaard-Poulsen H; Andersen AP; Loft H; Dombernowsky P; Andersen KW
    Breast Cancer Res Treat; 1986; 7 Suppl():S45-50. PubMed ID: 3527306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial.
    Fallowfield L; Cella D; Cuzick J; Francis S; Locker G; Howell A
    J Clin Oncol; 2004 Nov; 22(21):4261-71. PubMed ID: 15514369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinicel study on treatment of advanced primary liver cancer by Yanshu injection combining with chemotherapy].
    Guan CN; Cai LZ; Yue LQ; Zhang Y
    Zhongguo Zhong Yao Za Zhi; 2006 Mar; 31(6):510-2. PubMed ID: 16722388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cooperative research on post-operative adjuvant therapy of breast cancer. Tohoku Society of Adjuvant Chemo-endocrine Therapy of Breast Cancer].
    Abe R; Tsuchiya A; Koie H; Ono K; Abo S; Saito K; Tsukamoto M; Sato T; Mori S; Motoki R
    Gan To Kagaku Ryoho; 1988 Sep; 15(9):2707-12. PubMed ID: 3137888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study.
    Andersson M; Daugaard S; von der Maase H; Mouridsen HT
    Cancer Treat Rep; 1986 Oct; 70(10):1181-6. PubMed ID: 3530444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.
    Cella D; Fallowfield L; Barker P; Cuzick J; Locker G; Howell A;
    Breast Cancer Res Treat; 2006 Dec; 100(3):273-84. PubMed ID: 16944295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category?
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Neoplasma; 1999; 46(2):132-9. PubMed ID: 10466439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitomycin and tamoxifen versus mitolactol, doxorubicin, and tamoxifen in patients with previously treated breast cancer.
    Falkson G; Gelman RS; Tormey DC; Taylor SG; Falkson HC
    Cancer Treat Rep; 1985; 69(7-8):755-60. PubMed ID: 4016786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of Cepharanthin for preventing leukopenia and thrombocytopenia induced by chemotherapy in breast cancer patient--prospective randomized study].
    Suzuki S; Abe R; Nihei M; Kimijima I; Tsuchiya A; Nomizu T
    Gan To Kagaku Ryoho; 1990 Jun; 17(6):1195-200. PubMed ID: 2190537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
    Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
    Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.